Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Sees Strong Trading Volume – Should You Buy?

Recordati Industria Chimica E Farmaceutica S.P.A. (OTCMKTS:RCDTF) saw an uptick in trading volume on Friday . 200 shares traded hands during trading, an increase of 9% from the previous session’s volume of 184 shares.The stock last traded at $58.75 and had previously closed at $56.95.

Wall Street Analyst Weigh In

A number of research firms have issued reports on RCDTF. Barclays raised shares of Recordati Industria Chimica E Farmaceutica from a “strong sell” rating to a “hold” rating in a report on Thursday, February 12th. Kepler Capital Markets raised shares of Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 3rd. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy”.

Recordati Industria Chimica E Farmaceutica Stock Up 5.1%

The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $12.12 billion, a PE ratio of 22.23 and a beta of 0.26. The stock’s fifty day simple moving average is $56.59 and its 200-day simple moving average is $61.72.

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) last posted its quarterly earnings data on Wednesday, May 13th. The company reported $1.08 earnings per share (EPS) for the quarter. The firm had revenue of $834.86 million for the quarter. Recordati Industria Chimica E Farmaceutica had a net margin of 17.81% and a return on equity of 35.19%.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.

The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.